Jade Biosciences Outlines Key 2026 Objectives and Strategy to Advance Pipeline of Potentially Best-in-Class Monoclonal Antibodies Across Multiple Autoimmune Diseases Ahead of the 44th Annual J.P. Morgan Healthcare Conference

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• JADE201 has broad potential across a range of autoimmune diseases validated by BAFF-R biology

  80% confidence

• Jade's programs are designed to deliver deeper, more durable efficacy with a lower treatment burden for patients

  80% confidence

• Backed by a strong balance sheet with runway expected to last into the first half of 2028, Jade is poised to deliver meaningful benefit to patients, have impactful clinical catalysts, and drive long-term growth and value creation

  80% confidence

• Selective anti-APRIL therapies are poised to become foundational treatments in IgAN, potentially moving to frontline therapy by delivering disease-modifying efficacy

  80% confidence

• JADE201 has the potential to deliver deeper and more durable B-cell depletion than existing therapies, translating into enhanced efficacy and reduced treatment burden for patients

  80% confidence

• JADE101 has demonstrated ultra-high binding affinity in preclinical studies and its favorable preclinical safety, pharmacokinetic and pharmacodynamic profile supports the potential for infrequent dosing and a best-in-class therapeutic profile

  80% confidence

• 2026 is expected to be another year of rapid growth for Jade as we advance our pipeline across multiple clinical trials and transition toward late-stage development for JADE101

  80% confidence

Cited in these Via News reports

• Jade Biosciences Targets 2027 Phase 1 Trial as Global Autoimmune Drug Race Intensifies →
• The Dollar Nobody Controls: How Tether's USDT Is Filling the Void Left by Failed Currencies Worldwide →